The dose-dependency of the effects of 2 methyl 3 (phenylaminomethyl)-1h-quinolin-4 one – a promising antidepressant with nootropic properties

I. M. Podolsky, S. Yu. Shtrygol

Abstract


The object of the study is 2‑methyl-3‑(phenylaminomethyl)-1H-quinolin-4-one. According to the results of the screening of a series of 3-(N-R,R’-aminomethyl)-2-methyl-1H-quinolin-4-ones it has been proven that in the dose of 100 mg/kg it has the high antidepressant activity in tail suspension test (TST) and prevents scopolamine-induced amnesia development in passive avoidance test (PAT). The present post-screening study was carried out with the purpose of dose-dependency detalization using the doses of 5, 50, 100 and 150 mg/kg in TST and PAT after scopolamine-induced amnesia. The comparison of experimental results of screening and post-screening studies has allowed revealing relationships between the activity and the amount of the substance introduced in a wide range of doses. According to the results of TST in both studies it has been concluded that the only dose of 2‑methyl-3‑(phenylaminomethyl)-1H-quinolin-4-one, which provides a considerable antidepressant activity, is 100 mg/kg. The comparison of PAT results in screening and post-screening studies has been shown that in almost all doses studied, except 5 mg/kg, 2‑methyl-3‑(phenylaminomethyl)-1H-quinolin-4-one significantly attenuate the amnesic effect of scopolamine. Therefore, the effective dose of 2‑methyl-3‑(phenylaminomethyl)-1H-quinolin-4-one for in-depth studies is 100 mg/kg with both activities (antidepressant and anti-amnesic) at their maximum.


Keywords


2 methyl-3 (phenylaminomethyl)-1H-quinolin-4-one; dose-dependency; tail suspension test; passive avoidance test

References


Зубков В.А., Гриценко И.С., Таран С.Г. и др. // ЖОФХ. – 2005. – Т. 3, №2 (10). – С. 23-27.

Коваленко В.М. // Фармакол. та лікарська токсикол. – 2009. – Т. 12, №5. – 2009. – С. 56-61.

Лакин Г.Ф. Биометрия : Учеб. пособие для биол. спец. вузов. – М.: Высш. шк., 1990. – 352 с.

Настанова СТ-Н МОЗУ 42-6.0:2008. Лікарські засоби. Належна лабораторна практика (видання офіційне) / О. Стефанов, Т. Бухтіарова, В. Коваленко та ін. – К.: Моріон, 2009. – С. 37-68.

Радионова К.С., Бельник А.П., Островская Р.У. // Бюл. эксперим. биол. и медицины. – 2008. – Т. 146, №1. – С. 65-68.

Руководство по проведению доклинических исследований лекарственных средств. Ч. І / Под ред. А.Н.Миронова. – М.: Гриф и К, 2012. – 944 с.

Штриголь С.Ю., Зубков В.О., Гриценко І.С. та ін. // Клінічна фармація. – 2010. – Т. 14, №1. – С. 35-38.

Bammer G. // Neurosci. and Biobehavioral Rev. – 1982. – Vol. 6, №3. – P. 247-296.

Can A., Dao D.T., Terrillion C.E. et al. // J. of Visualized Experiments. – 2012. – Vol. 59. – e3769.

Deacon R.M. // Nature Protocols. – 2006. – Vol. 1, №2. – P. 936-946.

Drug Discovery and Evaluation: Pharmacological Assays / H.G.Vogel (ed.). – 3-rd Ed., Springer, Berlin, Heidelberg, New York, 2008. – P. 902-906.

Ebert U., Kirch W. // Eur. J. Clin. Invest. – 1998. – Vol. 28, №11. – P. 944-949.

Steru L., Chermat R., Thierry B., Simon P. // Psychopharmacol. (Berl). – 1985. – Vol. 85. – P. 367-370.


GOST Style Citations






DOI: https://doi.org/10.24959/cphj.16.1408

Abbreviated key title: Klìn. farm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)